Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Sep 20;43:264. doi: 10.1186/s13046-024-03158-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 5 — Longitudinal analyses of cfDNA/ctDNA allow for early detection and accurately reflect the disease kinetics. A. Swimmer plot of the 18 patients that underwent tumour progression divided based on the combinatorial approach with longitudinal samples collected at least 6 months prior to the relapse (cfDNA and ctDNA). B-D. Example figures of the cfDNA (blue dotted line) and ctDNA kinetics (yellow line) in patients with advanced disease. (1) Radiotherapy, (2) Carboplatin-Paclitaxel, (3) Dostarlimab, (4) Exemestane, (5) Doxorrubicin and Avastin, (6) Lenvatinib and Pembrolizumab, (7) Topotecan and Bevacizumab